These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3220459)

  • 1. Bone mineral content in normally menstruating women with hyperprolactinaemia.
    Nyström E; Leman J; Lundberg PA; Lindquist O; Hansson T; Bengtsson C; Rybo G; Lindstedt G
    Horm Res; 1988; 29(5-6):214-7. PubMed ID: 3220459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vertebral bone density in non-amenorrhoeic hyperprolactinaemic women.
    Ciccarelli E; Savino L; Carlevatto V; Bertagna A; Isaia GC; Camanni F
    Clin Endocrinol (Oxf); 1988 Jan; 28(1):1-6. PubMed ID: 3168298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone mineral density and bone turnover in hyperprolactinaemia of various origins.
    Zadrozna-Sliwka B; Bolanowski M; Kałuzny M; Syrycka J
    Endokrynol Pol; 2007; 58(2):116-22. PubMed ID: 17578827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone density in amenorrheic women with and without hyperprolactinemia.
    Schlechte JA; Sherman B; Martin R
    J Clin Endocrinol Metab; 1983 Jun; 56(6):1120-3. PubMed ID: 6404918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of other than prolactin hormones on bone mineral density in women with hyperprolactinaemia of various origins.
    Bolanowski M; Zadrozna-Sliwka B; Jawiarczyk A; Syrycka J
    Gynecol Endocrinol; 2010 Aug; 26(8):623-7. PubMed ID: 20218822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum prolactin bioactivity and immunoactivity in hyperprolactinaemic states.
    Smith CR; Butler J; Hashim I; Norman MR
    Ann Clin Biochem; 1990 Jan; 27 ( Pt 1)():3-8. PubMed ID: 2310154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of hyperprolactinaemia.
    Schlechte JA
    Baillieres Clin Endocrinol Metab; 1995 Apr; 9(2):359-66. PubMed ID: 7625989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence of hyperprolactinaemia and association with markers of autoimmune thyroid disease in survivors of the Whickham Survey cohort.
    Vanderpump MP; French JM; Appleton D; Tunbridge WM; Kendall-Taylor P
    Clin Endocrinol (Oxf); 1998 Jan; 48(1):39-44. PubMed ID: 9509066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hyperprolactinaemia and bone mineral density].
    Kostrzak A; Męczekalski B
    Pol Merkur Lekarski; 2015 Aug; 39(230):122-5. PubMed ID: 26319389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of hyperprolactinaemia in female premenopausal blood donors.
    Alpañés M; Sanchón R; Martínez-García MÁ; Martínez-Bermejo E; Escobar-Morreale HF
    Clin Endocrinol (Oxf); 2013 Oct; 79(4):545-9. PubMed ID: 23445257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in mineral content and biochemical bone markers at the menopause.
    Mazzuoli G; Minisola S; Valtorta C; Antonelli R; Tabolli S; Bigi F
    Isr J Med Sci; 1985 Nov; 21(11):875-7. PubMed ID: 4077482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone mineral content of amenorrheic and eumenorrheic athletes.
    Drinkwater BL; Nilson K; Chesnut CH; Bremner WJ; Shainholtz S; Southworth MB
    N Engl J Med; 1984 Aug; 311(5):277-81. PubMed ID: 6738640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Premenopausal bleeding associated with hyperprolactinaemia.
    Ratchev E; Dokumov S
    Maturitas; 1995 Apr; 21(3):197-200. PubMed ID: 7616868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactin and schizophrenia: clinical consequences of hyperprolactinaemia.
    Meaney AM; O'Keane V
    Life Sci; 2002 Jul; 71(9):979-92. PubMed ID: 12088758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychological distress in patients with hyperprolactinaemia.
    Reavley A; Fisher AD; Owen D; Creed FH; Davis JR
    Clin Endocrinol (Oxf); 1997 Sep; 47(3):343-8. PubMed ID: 9373457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vertebral body bone mineral content in hyperprolactinemic women.
    Koppelman MC; Kurtz DW; Morrish KA; Bou E; Susser JK; Shapiro JR; Loriaux DL
    J Clin Endocrinol Metab; 1984 Dec; 59(6):1050-3. PubMed ID: 6490793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polycystic ovary syndrome or hyperprolactinaemia: a study of mild hyperprolactinaemia.
    Su HW; Chen CM; Chou SY; Liang SJ; Hsu CS; Hsu MI
    Gynecol Endocrinol; 2011 Jan; 27(1):55-62. PubMed ID: 20504100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coexistence of macroprolactinaemia and hyperprolactinaemia in women with oligo-/amenorrhoea is associated with high risk of pituitary adenomas.
    Lewandowski KC; Gasior-Perczak D; Kowalska A; Lewinski A
    Gynecol Endocrinol; 2014 May; 30(5):385-7. PubMed ID: 24533748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of hyperprolactinemia on biohumoral parameters of bone metabolism in women of reproductive age on chronic hemodialysis].
    Petrović MS; Prelević GM; Balint-Perić LjA; Radmilović AV
    Srp Arh Celok Lek; 1992; 120(1-2):15-8. PubMed ID: 1641694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of hyperprolactinaemia with the use of the intervals for prolactin after macroforms separation.
    Beda-Maluga K; Pisarek H; Komorowski J; Swietoslawski J; Fuss-Chmielewska J; Winczyk K
    J Physiol Pharmacol; 2014 Jun; 65(3):359-64. PubMed ID: 24930507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.